Comparing the current results to its competitors, Compass Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.27 %, recorded in the same quarter.
Compass Therapeutics Inc , slower than the average decrease reported by the company's competitors of -74.33 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -74.33 %
Compass Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, focusing on the immuno-oncology subsector. This sector is marked by rapid technological advancements and strong intellectual property protections. The company faces competition from larger, well-funded biopharmaceutical, biotechnology, and therapeutics firms, as well as academic institutions, governmental agencies, and public and private research organizations. Named competitors include AbbVie, Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly, Genentech, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc., Roche Holding Ltd, and Sanofi S.A. The company also competes with smaller or early-stage companies and universities developing cancer therapeutics. Competitive success depends on product efficacy, safety, and convenience.
November 4, 2025
In the rapidly evolving field of oncology, biopharmaceutical companies are continuously striving to break new ground and deliver innovative therapies to patients confronting cancer. Compass Therapeutics, Inc. (Nasdaq: CMPX) stands at an intriguing intersection of scientific advancement and market dynamics as they recently unveiled promising preclinical data for their novel bispecific antibody, CTX-10726, at the esteemed 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting. This development is particularly noteworthy as it unfolds against a backdrop of challenging financial metrics in comparison to industry competitors. Innovative Science: CTX-10726 Preclinical Insights At the heart of Compass Thera...
August 6, 2024
Compass Therapeutics Completes Patient Enrollment in COMPANION-002: A Landmark Achievement in Biliary Tract Cancer Research BOSTON, Aug. 6, 2024 In a significant advancement in the realm of oncology, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company renowned for its focus on antibody-based therapeutics, has successfully completed patient enrollment in its COMPANION-002 trial. This Phase 2/3 randomized clinical study seeks to evaluate the efficacy of CTX-009 in conjunction with the chemotherapy agent Paclitaxel for patients diagnosed with biliary tract cancer (BTC).The completion of enrollment marks a pivotal moment in the trial s timeline, reaching the target of 150 pati...
February 28, 2024
CTX-8371, a fully-human, tetravalent bispecific antibody, stands out due to its unique mechanism-of-action which entails dual blockade of PD-1 and PD-L1 as well as cleavage of cell surface PD-1. By targeting both PD-1 and its ligand PD-L1, CTX-8371 aims to unleash the immune system s full potential in recognizing and eliminating cancer cells, resulting in enhanced anti-tumor activity. The preclinical data presented in the article highlighted CTX-8371 s superior performance compared to already approved anti-PD-1 blockers and anti-PD-L1 blockers across a range of in vitro and in vivo experimental models.Numerous studies have demonstrated the clinical significance of targeting the PD-1/PD-L1 pathway, which acts...
January 5, 2024
Compass Therapeutics Provides Corporate Update: Promising Progress in Oncology-focused Biopharmaceutical DevelopmentBOSTON, Jan. 05, 2024 Compass Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of proprietary antibody-based therapeutics, announced significant strides in their quest to combat multiple human diseases. With a specific focus on oncology, the company s recent advancements demonstrate their commitment to improving patients lives through innovative treatments. This press release outlines some key updates from Compass Therapeutics, including exciting new partnerships and advancements in their therapeutic pipeline.Compass Therapeutics continues to solidify ...
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
Sources:
Compass Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Compass Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
